ArticleERJ open research2026

Inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) as host-directed therapy for pneumonia-related acute respiratory distress syndrome: a multicentre, randomised, placebo-controlled phase 2a trial (GI-HOPE).

Susanne Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.